Abstract

BackgroundThe goal of our study is to investigate whether the methylation levels of AHCY and CBS promoters are related to the risk of cerebral infarction by detecting the methylation level of AHCY and CBS genes.MethodsWe extracted peripheral venous blood from 152 patients with cerebral infarction and 152 gender- and age-matched healthy controls, and determined methylation levels of AHCY and CBS promoters using quantitative methylation-specific polymerase chain reaction. We used the percentage of methylation reference (PMR) to indicate gene methylation level.ResultsWe compared the promoter methylation levels of two genes (AHCY and CBS) in peripheral blood DNA between the cerebral infarction case group and the control group. Our study showed no significant difference in AHCY promoter methylation between case and control. Subgroup analysis by gender showed that the methylation level of AHCY in males in the case group was lower than that in the control group, but the difference was not statistically significant in females. In a subgroup analysis by age, there was no significant difference in the AHCY methylation level between the case and control in the young group (≤44 years old). However, the level of AHCY gene methylation in the middle-aged group (45–59 years old) was significantly higher and the aged group (≥60 years old) was significantly lower than that in the control groups. However, CBS promoter methylation levels were significantly lower in the case group than in the control group (median PMR: 70.20% vs 104.10%, P = 3.71E-10). In addition, the CBS methylation levels of males and females in the case group were significantly lower than those in the control group (male: 64.33% vs 105%, P = 2.667E-08; female: 78.05% vs 102.8%, P = 0.003). We also found that the CBS levels in the young (23–44), middle-aged (45–59), and older (60–90) groups were significantly lower than those in the control group (young group: 69.97% vs 114.71%; P = 0.015; middle-aged group: 56.04% vs 91.71%; P = 6.744E-06; older group: 81.6% vs 119.35%; P = 2.644E-04). Our ROC curve analysis of CBS hypomethylation showed an area under the curve of 0.713, a sensitivity of 67.4%, and a specificity of 74.0%.ConclusionOur study suggests that hypomethylation of the CBS promoter may be closely related to the risk of cerebral infarction and may be used as a non-invasive diagnostic biomarker for cerebral infarction.

Highlights

  • The goal of our study is to investigate whether the methylation levels of AHCY and cystathionine beta-synthase (CBS) promoters are related to the risk of cerebral infarction by detecting the methylation level of AHCY and CBS genes

  • We examined the levels of AHCY and CBS promoter methylation in peripheral blood from patients with cerebral infarction and healthy controls

  • We examined the relative methylation levels of the AHCY and CBS genes in 152 patients with cerebral infarction and 152 healthy controls

Read more

Summary

Introduction

The goal of our study is to investigate whether the methylation levels of AHCY and CBS promoters are related to the risk of cerebral infarction by detecting the methylation level of AHCY and CBS genes. DNA methylation is an epigenetic modification that links the roles between heredity and the environment [6]. The level of SAM is closely related to DNA methylation. There are several DNA methylation studies related to stroke [9]. High homocysteine (Hcy) leads to hypermethylation of the TM gene and further induction of TM gene silencing, which may play an important role in the development and progression of ischemic brain injury [10]. DNA methylation of CDKN2B may play a potential role in arterial calcification in patients with cerebral infarction [11]. DNA methylation inhibitor Zebularine confers neuroprotective effects on the ischemic rat brain and further supports the hypothesis that DNA methyltransferase promotes delayed ischemic brain injury [13]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call